DOJ sets new Medicare fraud case record with $900M sweep

In what the Department of Justice (DOJ) is calling the “largest takedown ever” of Medicare fraud, 301 people, including 61 physicians, nurses, pharmacists and physical therapists, have been charged with approximately $900 million in false billings.

The number of arrests and total amount of alleged fraudulent activity tops last year’s record sweep, which charged 243 people with $712 million in false billings.

About half of the cases involve home health services, with 100 people charged with $220 million in alleged fraud in the Southern District Florida alone. In one case, nine people are being accused of running six home health companies in the Miami area for the sole purpose of submitting $24 million in phony Medicare claims for unnecessary services based on bribes and kickbacks.

“As this takedown should make clear, health care fraud is not an abstract violation or benign offense--it is a serious crime,” U.S. Attorney General Loretta Lynch said in a statement. “The wrongdoers that we pursue in these operations seek to use public funds for private enrichment. They target real people – many of them in need of significant medical care. They promise effective cures and therapies, but they provide none. Above all, they abuse basic bonds of trust--between doctor and patient; between pharmacist and doctor; between taxpayer and government--and pervert them to their own ends.”

The specific charges in the cases range from conspiracy to commit health care fraud to money laundering to identity theft. More than 60 percent of the defendants submitted their allegedly false claims to Medicare Part D, which the DOJ said is Medicare’s fastest-growing component.

 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.